PZRXQ (PZRXQ) Stock Price & Analysis
PZRXQ (PZRXQ) rose 0.00% to USD 0 as of June 10, 2026 at 12:25 UTC, according to Nexqual real-time market data.
PZRXQ last closed at USD 0; the session ranged USD 0–0 on volume of 250 shares. Market capitalization is $1,169, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 12:25 UTC.
Key Statistics (as of June 10, 2026 at 12:25 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 250 shares |
| Market Cap | $1,169 |
| Exchange | PNK |
Technical Analysis (PZRXQ)
Nexqual's technical model rates PZRXQ "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 12:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (PZRXQ)
Wall Street analysts rate PZRXQ "None", per Nexqual as of June 10, 2026 at 12:25 UTC.
| Consensus Rating | None |
|---|
Earnings (PZRXQ)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2017-09-30 | USD -0.23 vs est -0.32 ▲ beat |
| 2017-06-30 | USD -0.3 vs est -0.35 ▲ beat |
| 2017-03-31 | USD -0.35 vs est -0.29 ▼ miss |
| 2016-12-31 | USD -0.3 vs est -0.37 ▲ beat |
Source: Nexqual, June 10, 2026 at 12:25 UTC.
Financials & Fundamentals (PZRXQ)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -228.17% |
| Current Ratio | 2.14 |
| Total Cash | $5.26M |
| Total Debt | $5.44M |
| Free Cash Flow | $-7.68M |
Source: Nexqual, June 10, 2026 at 12:25 UTC.
Financial Health Score (PZRXQ)
Nexqual rates PZRXQ's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 12:25 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $5M cash vs $5M debt |
| Cash Flow | Weak — Operating cash flow -$13M |
| Efficiency | Critical — ROE -228%, ROA -64.2% |
Ownership (PZRXQ)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 11.69M |
| Float | 5.08M |
| Short % of Float | +2.53% |
Source: Nexqual, June 10, 2026 at 12:25 UTC.
Leadership (PZRXQ)
PZRXQ is led by Robert W. Overell (age 69), Co-Founder & Director, per Nexqual as of June 10, 2026 at 12:25 UTC.
| Co-Founder & Director | Robert W. Overell (age 69) |
|---|---|
| Co-Founder & Director | Paul H. Johnson (age 82) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PFND | PATHFINDER CELL THERAPY INC | USD 0 | ▲ 0% |
| ROSGQ | ROSETTA GENOMICS LTD | USD 0 | ▲ 0% |
| TNGNQ | TENGION INC | USD 0 | ▲ 0% |
| RGDXQ | RESPONSE GENETICS INC | USD 0 | ▲ 0% |
| SNNAQ | Sienna Biopharmaceuticals, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:25 UTC. This page is informational and not investment advice.